SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Read more breaking news

 

 
Dispatches from Vitafoods Europe 2014

Pharmachem: EFSA cranberry rejection doesn’t affect our European business

By Shane Starling+

07-May-2014
Last updated on 09-May-2014 at 00:16 GMT2014-05-09T00:16:45Z

Pharmachem-Proprietary Nutritionals: “Obviously we are disappointed by this but it doesn’t affect our interest in growing our business in Europe.”

Pharmachem-Proprietary Nutritionals: “Obviously we are disappointed by this but it doesn’t affect our interest in growing our business in Europe.”

New Jersey supplier Pharmachem says a European Food Safety Authority (EFSA) rejection of its ‘CranMax’ cranberry ingredient’s ability to prevent urinary tract infection (UTI) in women won’t change its European business plans.

While French supplier Naturex indicated it would turn its attention to other markets after its own ‘Pacran’ cranberry extract was also rebuffed by EFSA, president of Pharmachem subsidiary Proprietary Nutritionals, Dean Mosca, said the firm was disappointed by the rejection, but not disheartened about European prospects in cranberry supplements.

“We continue to see Europe as a large and interesting market,” Mosca told us from the booth of Ingredia – its French-based distributor – at Vitafoods Europe in Geneva.

“Obviously we are disappointed by this but it doesn’t affect our interest in growing our business in Europe.”

But he added: “It does however affect our will to conduct research. The problem here that is not the same in other parts of the world, is that the regulatory ambiguity makes it very hard to determine return on investment. But we will look at the opinion in more detail and hope for further guidance on this.”

Pharmachem-Proprietary Nutritionals did not actually submit the claim rather Danish pharma and supplements manufacturer Jemo-pharm A/S, whose article 13.5 claim submission was based on CranMax.

“One human study from which conclusions could be drawn for the scientific substantiation of the claim did not show an effect of CranMax on reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract,” said EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) of the claim.

The opinion can be found here .

CranMax 

For the other rejection delivered this month by EFSA, Naturex defended its ingredient.

“We stand behind Pacran’s robust clinical evidence,” said Naturex marketing director, Antoine Dauby, yesterday, noting an approved claim by the Korean Food and Drug Administration (KFDA).

“We will continue to pursue permissible health claims in other countries and to help women suffering from recurrent UTIs in Europe and the rest of the world.”

Naturex acquired the ‘Pacran’ extract in question from Decas Botanical Synergies in 2012.

That article 13.5 emerging and proprietary science opinion can be found here .

No cranberry-based claim has yet been approved under the EU nutrition and health claims regulation (NHCR) for UTI. 

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars